- Home
- CDNA vs PTA Comparison
CDNA vs PTA Comparison
Compare CDNA & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- PTA
- Stock Information
- Founded
- CDNA 1998
- PTA 2020
- Country
- CDNA United States
- PTA United States
- Employees
- CDNA N/A
- PTA N/A
- Industry
- CDNA Medical Specialities
- PTA Trusts Except Educational Religious and Charitable
- Sector
- CDNA Health Care
- PTA Finance
- Exchange
- CDNA Nasdaq
- PTA Nasdaq
- Market Cap
- CDNA 1.1B
- PTA 1.1B
- IPO Year
- CDNA 2014
- PTA N/A
- Fundamental
- Price
- CDNA $23.16
- PTA $19.96
- Analyst Decision
- CDNA Buy
- PTA
- Analyst Count
- CDNA 8
- PTA 0
- Target Price
- CDNA $26.43
- PTA N/A
- AVG Volume (30 Days)
- CDNA 823.5K
- PTA 159.2K
- Earning Date
- CDNA 02-26-2025
- PTA 01-01-0001
- Dividend Yield
- CDNA N/A
- PTA 8.31%
- EPS Growth
- CDNA N/A
- PTA N/A
- EPS
- CDNA N/A
- PTA N/A
- Revenue
- CDNA $312,775,000.00
- PTA N/A
- Revenue This Year
- CDNA $20.27
- PTA N/A
- Revenue Next Year
- CDNA $11.76
- PTA N/A
- P/E Ratio
- CDNA N/A
- PTA N/A
- Revenue Growth
- CDNA 5.26
- PTA N/A
- 52 Week Low
- CDNA $7.42
- PTA $15.84
- 52 Week High
- CDNA $34.84
- PTA $19.67
- Technical
- Relative Strength Index (RSI)
- CDNA 47.43
- PTA 61.24
- Support Level
- CDNA $22.50
- PTA $19.80
- Resistance Level
- CDNA $23.81
- PTA $20.03
- Average True Range (ATR)
- CDNA 1.21
- PTA 0.16
- MACD
- CDNA 0.03
- PTA 0.05
- Stochastic Oscillator
- CDNA 49.08
- PTA 81.95
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.